Germany· DE-A57-decce3bba2003406
Impavido
A miltefosine product containing miltefosine, registered in Germany by Paesel + Lorei Gmbh & Co. Kg. The same ATC class is registered in 6 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Miltefosine is registered in 6 of 19 countries.
Countries holding a registration under ATC P01CX04 (miltefosine), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 4 of them publish a price we can compare per daily dose
Miltefosine · ATC P01CX04
6 / 19 countries
- Czechiaprice
- Finlandprice
- Germany
- Norwayprice
- United Kingdom
- United Statesprice
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Miltefosine
- Manufacturer
- Paesel + Lorei Gmbh & Co. Kg
- Country
- Germany (DE)
- ATC code
- P01CX04
- ATC class
- Miltefosine
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
16 interactions on record for miltefosine.
Graded by severity as the source publishes them — 16 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Miltefosine · interactions on record
16 records
- 16 moderate
Most severe, free to view
- IUP aus Plastik mit GestagenG02BA03moderate
- Levonorgestrel and ethinylestradiolG03AA07moderate
- Desogestrel and ethinylestradiolG03AA09moderate
- Drospirenone and ethinylestradiolG03AA12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Miltefosine in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ca817e7f-b7d6-45b8-bffa-76bf841ca5b1 GET /v1/drugs/ca817e7f-b7d6-45b8-bffa-76bf841ca5b1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Miltefosine",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about miltefosine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.